Zenocutuzumab在NRG1融合阳性实体瘤中显示疗效

IF 82.2 1区 医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2025-02-20 DOI:10.1038/s41571-025-01005-1
Diana Romero
{"title":"Zenocutuzumab在NRG1融合阳性实体瘤中显示疗效","authors":"Diana Romero","doi":"10.1038/s41571-025-01005-1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 5","pages":"308-308"},"PeriodicalIF":82.2000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours\",\"authors\":\"Diana Romero\",\"doi\":\"10.1038/s41571-025-01005-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"22 5\",\"pages\":\"308-308\"},\"PeriodicalIF\":82.2000,\"publicationDate\":\"2025-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41571-025-01005-1\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41571-025-01005-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

NRG1编码一种来自EGF家族的生长因子,其融合产生的嵌合蛋白促进HER2-HER3异源二聚化和随后的细胞增殖的致癌激活。这些融合发生在1%的实体肿瘤中,包括非小细胞肺癌(NSCLC)和胰腺腺癌(PDAC)。现在,来自energy II期试验的数据表明,HER2 × HER3双特异性抗体zenocutuzumab对晚期NRG1融合阳性实体瘤患者有效且安全。主要有效人群包括158名患有10种实体肿瘤类型之一的患者,主要是NSCLC (n = 94)和PDAC (n = 36)。大多数患者既往接受过转移性疾病的全身治疗,其中NSCLC和PDAC患者分别占77%和92%。主要终点为客观缓解率(ORR)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
99.40
自引率
0.40%
发文量
114
审稿时长
6-12 weeks
期刊介绍: Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
期刊最新文献
Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC. Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons. Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer. Clinical implementation of multi-cancer early detection tests: can we find a path forward? Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy - a full-circle moment for nasopharyngeal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1